The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 22 November 2005, www.theannals.com, DOI 10.1345/aph.1G142.
 The Annals of Pharmacotherapy: Vol. 40, No. 1, pp. 66-73. DOI 10.1345/aph.1G142
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franks, A. M
Right arrow Articles by Gardner, S. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franks, A. M
Right arrow Articles by Gardner, S. F

NEW DRUG DEVELOPMENTS

AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis

Amy M Franks, PharmD

Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR

Stephanie F Gardner, PharmD EdD

Professor and Dean, College of Pharmacy, University of Arkansas for Medical Sciences

Reprints: Dr. Franks, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot 522, Little Rock, AR 72205-7199, fax 501/296-1168, afranks{at}uams.edu

OBJECTIVE: To review the synthesis, pharmacology, clinical trials, and adverse effects of AGI-1067, a novel agent for preventing restenosis.

DATA SOURCES: Literature searches were conducted using MEDLINE (1966–July 2005) and International Pharmaceutical Abstracts (1970–July 2005) for English-language articles containing the search terms AGI-1067, AGI 1067, and probucol. In addition, bibliographies from relevant articles were reviewed for additional references.

STUDY SELECTION AND DATA EXTRACTION: All articles identified from data sources were reviewed for relevant information. Applicable information was included in this review.

DATA SYNTHESIS: AGI-1067, a derivative of the lipid-lowering agent probucol, is the first of a new class of drugs termed vascular protectants. It has antioxidant and lipid-lowering effects. In addition, it inhibits inflammatory processes without resultant immunosuppression through its selective inhibition of vascular cell adhesion molecule-1 expression. AGI-1067 also exhibited anti-atherosclerotic effects in preclinical studies. Relatively short-term treatment with AGI-1067 showed positive results compared with probucol in preventing restenosis in patients undergoing percutaneous coronary intervention. AGI-1067 appears to be well tolerated and holds important advantages over probucol in that it has fewer adverse effects on high-density lipoprotein cholesterol and the QT interval.

CONCLUSIONS: The favorable safety profile of AGI-1067 offers potential advantages over its precursor, probucol. Preclinical and clinical studies indicate that it possesses antioxidant, antiinflammatory, and lipid-lowering properties. Ongoing Phase II and III studies will determine AGI-1067's place in therapy for the prevention of restenosis and reduction in cardiovascular events in patients undergoing percutaneous intervention for coronary atherosclerosis.

Key Words: AGI-1067, probucol, restenosis

Published Online, November 22, 2005. www.theannals.com, DOI 10.1345/aph.1G142




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.